Imunon, Inc. (IMNN) Income Statement
IMNN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIMNN revenue and net income
IMNN profit margins
IMNN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IMNN quarterly EPS vs estimates
Imunon beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.61).
IMNN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $125,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 |
| Cost of revenue | — | $718,116 | $720,005 | $731,629 | $702,918 | $11.3M | $13.1M | $11.1M | $13.1M | $0 |
| Gross profit | — | −$718,116 | −$720,005 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 |
| Research & development | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M | $14.6M |
| Sales, general & admin | $6.9M | $7.5M | $9.7M | $13.7M | $10.9M | $7.6M | $8.0M | $9.7M | $5.9M | $6.5M |
| Total operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M | $19.0M | $21.1M | $21.6M | $19.0M | $21.1M |
| Operating income | −$14.7M | −$19.1M | −$21.0M | −$24.9M | −$21.0M | −$18.5M | −$20.6M | −$21.1M | −$18.5M | −$20.6M |
| Interest income | — | $450,221 | $1.2M | $502,578 | $18,145 | $66,553 | $442,987 | $331,780 | — | — |
| Interest expense | — | $0 | $197,080 | $5.0M | $569,881 | $1.3M | $1.4M | $712,025 | $91,756 | $722,993 |
| Income before taxes | −$14.5M | −$18.6M | −$20.8M | −$37.5M | −$22.2M | −$23.3M | −$18.7M | −$22.3M | −$20.4M | −$22.1M |
| Income taxes | — | — | −$1.3M | −$1.6M | −$1.4M | −$1.8M | −$1.8M | −$10.4M | $1.9M | $1.4M |
| Net income | −$14.5M | −$18.6M | −$19.5M | −$35.9M | −$20.8M | −$21.5M | −$16.9M | −$11.9M | −$20.4M | −$22.1M |
| EBITDA | −$13.8M | −$17.9M | −$19.9M | −$31.7M | −$20.9M | −$21.3M | −$16.6M | −$21.2M | −$19.8M | −$20.3M |
| EPS (diluted) | −$7.98 | −$18.11 | −$21.68 | −$48.05 | −$17.61 | −$94.96 | −$148.70 | −$193.98 | −$624.91 | −$1847.74 |
| Gross margin | — | — | −576.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | — | — | −16,824.3% | −4,984.3% | −4,201.4% | −3,697.3% | −4,113.1% | −4,213.0% | −3,693.7% | −4,130.0% |
| Net margin | — | — | −15,612.0% | −7,179.6% | −4,153.9% | −4,296.7% | −3,370.3% | −2,376.7% | −4,080.4% | −4,410.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $727,160 | $0 | $0 | $0 | $7.1M | $0 |
| Cost of revenue | — | $166,544 | $169,265 | $167,034 | $164,674 | $2.2M | $165,286 | $3.3M | $185,270 | $178,310 | $140,556 | $198,292 |
| Gross profit | — | −$166,544 | −$169,265 | −$167,034 | −$164,674 | −$2.2M | −$165,286 | −$3.3M | −$185,270 | −$178,310 | $6.9M | −$198,292 |
| Research & development | $1.5M | $2.3M | $2.5M | $1.9M | $1.2M | $2.2M | $2.2M | $3.3M | $2.8M | $3.3M | $3.6M | $2.0M |
| Sales, general & admin | $1.3M | $1.97B | $1.8M | $1.6M | $1.5M | $2.0M | $1.9M | $1.7M | $2.2M | $1.7M | $2.4M | $1.9M |
| Total operating expenses | $2.8M | $4.1M | $4.3M | $3.5M | $2.6M | $2.0M | $4.0M | $1.7M | $5.0M | $5.0M | $6.0M | $3.9M |
| Operating income | −$2.8M | −$4.3M | −$4.3M | −$3.5M | −$2.8M | −$4.1M | −$4.1M | −$5.0M | −$5.0M | −$5.0M | −$6.0M | −$3.9M |
| Interest income | — | — | — | — | — | — | $88,957 | $115,992 | $89,884 | $155,387 | $209,460 | $264,284 |
| Interest expense | $77,273 | — | — | — | — | — | $0 | $0 | $0 | $0 | $209,460 | $0 |
| Income before taxes | −$2.8M | −$4.2M | −$4.2M | −$3.4M | −$2.7M | −$4.1M | −$4.1M | −$4.8M | −$4.8M | −$4.9M | −$4.9M | −$3.5M |
| Income taxes | — | — | — | — | — | — | −$135,034 | — | — | $135,034 | −$1.3M | $237,878 |
| Net income | −$2.8M | −$4.2M | −$4.2M | −$3.4M | −$2.7M | −$4.1M | −$4.1M | −$4.8M | −$4.8M | −$4.9M | −$4.9M | −$3.5M |
| EBITDA | −$2.6M | −$4.1M | −$4.1M | −$3.3M | −$2.6M | −$4.0M | −$3.9M | −$4.8M | −$4.6M | −$4.8M | −$6.0M | −$3.3M |
| EPS (diluted) | −$0.54 | −$0.84 | −$1.30 | −$1.16 | −$1.87 | −$3.65 | −$0.25 | −$4.43 | −$6.65 | −$6.78 | −$0.52 | −$4.83 |
| Gross margin | — | — | — | — | — | — | −22.7% | — | — | — | 98.0% | — |
| Operating margin | — | — | — | — | — | — | −570.2% | — | — | — | −84.6% | — |
| Net margin | — | — | — | — | — | — | −558.0% | — | — | — | −69.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IMNN's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IMNN financial results
Imunon reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $14.5 million. Diluted earnings per share came to −$7.98.
See the IMNN stock overview for the latest quote and news, or the IMNN chart for price history and technical indicators.
IMNN income statement FAQ
Does Imunon have revenue?
Imunon reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Imunon profitable?
No. Imunon reported a net loss of $14.5 million in fiscal 2025.
How much does Imunon spend on research and development?
Imunon spent $7.8 million on research and development in fiscal 2025.
What are Imunon's earnings per share?
Imunon earned $-7.98 per diluted share in fiscal 2025, compared with $-18.11 a year earlier.
When will Imunon report its next earnings?
Imunon is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Imunon's fiscal year end?
Imunon's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.